Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/29740
Title: | EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate |
Authors: | Bibbò, S Capone, E Lovato, G Lamolinara, A Ponziani, S Iezzi, M Lattanzio, R Mazzocco, K Morini, M Giansanti, F De Laurenzi, V Whitfield, J Iacobelli, S Ippoliti, R Beaulieu, ME Soucek, L Sala, A Sala, G |
Keywords: | MYCN;Omomyc;HER3;immunoconjugates;target therapy |
Issue Date: | 14-Aug-2024 |
Publisher: | Elsevier |
Citation: | Bibbò, S. et al. (2024) 'EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate', Journal of Controlled Release, 374, pp. 171 - 180. doi: 10.1016/j.jconrel.2024.08.009. |
Abstract: | MYC is one of the most important therapeutic targets in human cancer. Many attempts have been made to develop small molecules that could be used to curb its activity in patients, but most failed to identify a suitable direct inhibitor. After years of preclinical characterization, a tissue-penetrating peptide MYC inhibitor, called Omomyc, has been recently successfully used in a Phase I dose escalation study in late-stage, all-comers solid tumour patients. The study showed drug safety and positive signs of clinical activity, prompting the beginning of a new Phase Ib combination study currently ongoing in metastatic pancreatic adenocarcinoma patients. In this manuscript, we have explored the possibility to improve Omomyc targeting to specific cancer subtypes by linking it to a therapeutic antibody. The new immunoconjugate, called EV20/Omomyc, was developed by linking a humanised anti-HER3 antibody, named EV20, to Omomyc using a bifunctional linker. EV20/Omomyc shows antigen-dependent penetrating activity and therapeutic efficacy in a metastatic model of neuroblastoma. This study suggests that directing Omomyc into specific cell types using antibodies recognising tumour antigens could improve its therapeutic activity in specific indications, like in the paediatric setting. |
Description: | Data availability: Data will be made available on request. Supplementary data are available online at: https://www.sciencedirect.com/science/article/pii/S0168365924005480#s0125 . |
URI: | https://bura.brunel.ac.uk/handle/2438/29740 |
DOI: | https://doi.org/10.1016/j.jconrel.2024.08.009 |
ISSN: | 0168-3659 |
Other Identifiers: | ORCiD: Arturo Sala https://orcid.org/0000-0002-2841-7866 |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/bync-nd/4.0/). | 4.33 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License